A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(13 sites)

United States

University of Arkansas for Medical Sciences, Little Rock, Arkansas

University of California, Irvine, Irvine, California

University of California, San Francisco, San Francisco, California

Emory Winship Cancer Institute, Atlanta, Georgia

Boston Medical Center, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Henry Ford Cancer Center, Detroit, Michigan

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

Canada

Princess Margaret Cancer Centre, Toronto